A phase II efficacy and safety, open-label, multicenter study of imprime PGG injection in combination with cetuximab in patients with stage IV KRAS-mutant colorectal cancer Journal Article
| Authors: | Segal, N. H.; Gada, P.; Senzer, N.; Gargano, M. A.; Patchen, M. L.; Saltz, L. B. |
| Article Title: | A phase II efficacy and safety, open-label, multicenter study of imprime PGG injection in combination with cetuximab in patients with stage IV KRAS-mutant colorectal cancer |
| Abstract: | Micro-Abstract Cetuximab alone is ineffective in KRAS-mutant colorectal cancer. Imprime PGG (β(1,6)-[poly-(1,3)-D-glucopyranosyl]-poly-β(1,3)-D-glucopyranose), a yeast-derived beta-glucan polymer, activates innate immune effector cells enabling recognition and killing of tumor coated by a complement-activating antibody, such as cetuximab. In this phase II study, immune therapy for KRAS-mutant colorectal cancer with Imprime PGG plus cetuximab was assessed. The combination was safe and compelling, albeit modest, clinical activity was shown. © 2016 Elsevier Inc. |
| Keywords: | epidermal growth factor receptor; antibody; complement; immune; β-glucan |
| Journal Title: | Clinical Colorectal Cancer |
| Volume: | 15 |
| Issue: | 3 |
| ISSN: | 1533-0028 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2016-09-01 |
| Start Page: | 222 |
| End Page: | 227 |
| Language: | English |
| DOI: | 10.1016/j.clcc.2016.02.013 |
| PROVIDER: | scopus |
| PUBMED: | 26975418 |
| PMCID: | PMC5621519 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 6 December 2016 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work